Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,664 JPY | +1.87% | +1.93% | +1.15% |
04-25 | AstraZeneca upbeat as cancer drugs underpin sales growth | AN |
04-08 | AstraZeneca hails neurological data for Ultomiris, Soliris | AN |
Sales 2024 * | 201B 1.27B 101B | Sales 2025 * | 198B 1.25B 100B | Capitalization | 365B 2.3B 184B |
---|---|---|---|---|---|
Net income 2024 * | 52.51B 332M 26.55B | Net income 2025 * | 52.26B 330M 26.42B | EV / Sales 2024 * | 1.82 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 1.84 x |
P/E ratio 2024 * |
7.62
x | P/E ratio 2025 * |
7.36
x | Employees | 864 |
Yield 2024 * |
5.31% | Yield 2025 * |
5.45% | Free-Float | 46.97% |
1 day | +1.87% | ||
1 week | +1.93% | ||
Current month | -0.63% | ||
1 month | -2.09% | ||
3 months | -5.26% | ||
6 months | +34.81% | ||
Current year | +1.15% |
Managers | Title | Age | Since |
---|---|---|---|
Akihiko Ishihara
CEO | Chief Executive Officer | 61 | 31/03/86 |
Chairman | 71 | 01/04/77 | |
Sou Busujima
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 71 | 01/04/77 | |
Akihiko Ishihara
CEO | Chief Executive Officer | 61 | 31/03/86 |
Ichiro Tomiyama
COO | Chief Operating Officer | 66 | 31/10/86 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.78% | 9 M€ | +17.30% |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 1,664 | +1.87% | 1,546,700 |
25/04/24 | 1,633 | -1.98% | 772,100 |
24/04/24 | 1,666 | +0.97% | 1,043,900 |
23/04/24 | 1,650 | +0.49% | 831,300 |
22/04/24 | 1,642 | +0.61% | 1,447,400 |
Delayed Quote Japan Exchange, April 26, 2024 at 07:00 am
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.15% | 2.32B | |
+11.20% | 8.25B | |
-25.64% | 703M | |
+29.76% | 358M | |
+3.88% | 327M | |
+5.69% | 349M | |
-6.11% | 270M | |
+15.54% | 182M | |
+26.63% | 99.29M | |
-28.33% | 63.25M |
- Stock Market
- Equities
- 6417 Stock